Treatment of Cutaneous Vasculitis

Initial Assessment and Disease Severity Stratification

• The American College of Rheumatology and the Vasculitis Foundation guidelines distinguish between isolated cutaneous vasculitis and systemic vasculitis with cutaneous manifestations, as treatment differs substantially 1, 2
• The 2021 ACR/Vasculitis Foundation guidelines explicitly exclude isolated cutaneous vasculitis from systemic polyarteritis nodosa treatment protocols, as cutaneous-limited disease is managed differently 1, 3, 4
• Nonsevere cutaneous disease is characterized by uncomplicated skin lesions without organ-threatening features 1, 2
• Systemic involvement is defined as life- or organ-threatening manifestations demanding immediate immunosuppression 1, 2

Treatment Algorithm for Systemic Vasculitis with Cutaneous Involvement

• The European League Against Rheumatism recommends immediate high-dose glucocorticoids combined with cyclophosphamide (or rituximab) for gangrene or severe organ-threatening cutaneous vasculitis 5, 6
• High-dose glucocorticoids, such as prednisone 1 mg/kg/day, are used for severe disease 1, 2, 5, 6
• Cyclophosphamide is combined with glucocorticoids for severe disease 1, 5, 6
• Rituximab is an alternative to cyclophosphamide, particularly for refractory cases, with a 91% remission rate in open-label trials 7

Maintenance Therapy

• The European League Against Rheumatism recommends maintaining high-dose glucocorticoids for a minimum of 1 month before gradual taper 5, 6
• Azathioprine 1-2 mg/kg/day is used for maintenance after remission induction 5, 6
• Maintenance therapy should continue for at least 18 months in complete remission 5, 6

Adjunctive Therapies

• Pneumocystis prophylaxis with trimethoprim-sulfamethoxazole is recommended for all patients receiving cyclophosphamide 5, 6
• Bone protection with calcium, vitamin D, and bisphosphonates is recommended for all patients on glucocorticoids 5, 6

Refractory Disease Options

• Intravenous immunoglobulin (IVIG) 2 g/kg over 5 days is used for persistent low activity 7
• Mycophenolate mofetil 2 g/day is used for refractory cases 7
• Rituximab 375 mg/m² weekly for 4 weeks is highly effective (91% remission) in refractory ANCA-associated vasculitis 7

Treatment of Cutaneous Small Vessel Vasculitis

Diagnostic Workup and Treatment Algorithm

• The Kidney International guideline recommends laboratory assessment for systemic involvement, including complete blood count, ESR/CRP, kidney function, urinalysis, complement levels, ANCA testing, and cryoglobulins in patients with cutaneous small vessel vasculitis 8
• The Annals of the Rheumatic Diseases suggests that patients with checkpoint inhibitor therapy may develop vasculitis with atypical features, and prompt rheumatology consultation is essential, with median time to evaluation ideally under 7-10 days 9
• The Kidney International guideline advises against delaying treatment in rapidly deteriorating patients with positive MPO/PR3-ANCA and compatible clinical presentation while waiting for biopsy results, and recommends immediate induction therapy with high-dose glucocorticoids and cyclophosphamide or rituximab 8
• The Kidney International guideline recommends maintenance therapy with azathioprine 1-2 mg/kg/day for at least 18 months in complete remission, and continuation of maintenance immunosuppression to prevent relapse 8

Special Considerations

• The Kidney International guideline notes that approximately 10% of patients with clinical small-vessel vasculitis are persistently ANCA-negative, but are treated identically to ANCA-positive patients, with careful exclusion of vasculitis mimics 8
• The Annals of the Rheumatic Diseases recommends prompt rheumatology consultation for patients with checkpoint inhibitor therapy who develop vasculitis with atypical features, with autoantibodies often absent despite clinical vasculitis 9

Management of Systemic Involvement in Cutaneous Small‑Vessel Vasculitis

Renal Involvement

The presence of renal manifestations such as hematuria, proteinuria, or rising serum creatinine signals systemic vasculitis and warrants immediate aggressive immunosuppression with high‑dose glucocorticoids (e.g., prednisone ≈ 1 g/kg/day) combined with cyclophosphamide or rituximab. 10

Pulmonary Involvement

Pulmonary signs—including hemoptysis, infiltrates on imaging, or hypoxemia—also indicate systemic disease and require the same high‑dose glucocorticoid‑plus‑cyclophosphamide/rituximab regimen. 10

Neurologic Involvement

Neurologic complications such as mononeuritis multiplex or motor neuropathy denote systemic vasculitis; treatment should follow systemic protocols with high‑dose glucocorticoids and either cyclophosphamide or rituximab. [11][10]

Mixed Cryoglobulinemia Consideration

Mixed cryoglobulinemia, frequently associated with hepatitis C infection, can present with palpable purpura mimicking isolated cutaneous vasculitis; however, it requires disease‑specific therapy rather than the standard cutaneous‑only approach. 12